Shots:
- Tempus AI has reported clinical launch of the ArteraAI Prostate Test (mHSPC), a CLIA-certified & CAP-accredited prognostic assay designed for pts with metastatic hormone-sensitive prostate cancer (mHSPC)
- ArteraAI Prostate Test (mHSPC) is an externally developed digital pathology algorithm clinically available through the Tempus AI ecosystem, with full platform integration to support personalized treatment decisions for urologists & oncologists
- The AI-powered tool evaluates both clinical data & histopathology biopsy images to generate personalized risk estimates for prostate cancer-specific mortality. By integrating Tempus’ NGS-based genomic profiling with Artera’s pathology-based AI insights, the platform aims to improve disease assessment & therapy intensity selection in prostate cancer
Ref: Businesswire | Image: Tempus AI | Press Release
Related News: Tempus AI Receives the US FDA’s 510(k) Clearance for Updated Tempus Pixel Cardiac Imaging Platform
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
